Expert Interview
An international look at Quviviq prescribing patterns since its FDA approval in May for treatment in adults with insomnia and how it compares to Merck's Belsomra and Eisai's Dayvigo.
Ticker(s): IDRSF, MRK, ESALYInstitution: University of Montpellier
- Professor of Neurology and Physiology, and Head of the clinical and research activity of the sleep laboratory at the University of Montpellier
- Coordinator of the French National Reference Network for Orphan Diseases (Narcolepsy, Hypersomnia, Kleine-Levin Syndrome) and Director of one research group in the Institute of Neuroscience(INSERM) at Montpellier
- Author or coauthor of more than 450 papers published in international and national peer-reviewed journals, several book chapters, and he also edited three French book related to sleep medicine.
- treats 2000 patients for insomnia
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
